טוען...
Glucagon‐like peptide‐1 receptor expression in the human eye
Semaglutide is a human glucagon‐like peptide‐1 (GLP‐1) analogue that is in development for the treatment of type 2 diabetes. In the pre‐approval cardiovascular outcomes trial SUSTAIN 6, semaglutide was associated with a significant increase in the risk of diabetic retinopathy (DR) complications vs p...
שמור ב:
| הוצא לאור ב: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Blackwell Publishing Ltd
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6099507/ https://ncbi.nlm.nih.gov/pubmed/29707863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13339 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|